Apoptosome dysfunction in human cancer by Hajra, Karen M. & Liu, J. Rebecca
Apoptosis 2004; 9: 691–704
C© 2004 Kluwer Academic Publishers
Apoptosome dysfunction in human cancer
K. M. Hajra and J. R. Liu
Department of Obstetrics and Gynecology, University of Michigan Medical School, L4000 Women’s Hospital,
1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
Apoptosis is a cell suicide mechanism that enables or-
ganisms to control cell number and eliminate cells that
threaten survival. The apoptotic cascade can be triggered
through two major pathways. Extracellular signals such
as members of the tumor necrosis factor (TNF) family can
activate the receptor-mediated extrinsic pathway. Alterna-
tively, stress signals such as DNA damage, hypoxia, and
loss of survival signals may trigger the mitochondrial in-
trinsic pathway. In the latter, mitochondrial damage re-
sults in cytochrome c release and formation of the apop-
tosome, a multimeric protein complex containing Apaf-1,
cytochrome c, and caspase-9. Once bound to the apopto-
some, caspase-9 is activated, and subsequently triggers
a cascade of effector caspase activation and proteolysis,
leading to apoptotic cell death. Recent efforts have led to
the identification of multiple factors that modulate apop-
tosome formation and function. Alterations in the expres-
sion and/or function of these factors may contribute to the
pathogenesis of cancer and resistance of tumor cells to
chemotherapy or radiation. In this review we discuss how
disruption of normal apoptosome formation and function
may lead or contribute to tumor development and pro-
gression.
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Introduction
The major apoptosis pathways
Apoptosis is an evolutionarily conserved, genetically con-
trolled process of programmed cell death, used by mul-
ticellular organisms to eliminate cells in diverse phys-
iological settings, such as development, homeostasis of
tissues, and maintenance of integrity of the organism.1,2
Intense work over the past several years has lead to the
identification of molecules involved in the control and
implementation of cell death. Disruption of the normal
apoptotic machinery contributes to a number of human
disorders, including cancer, immunodeficient and autoim-
mune states, and neurodegenerative diseases. Thus, un-
derstanding the molecular mechanism and regulation of
normal apoptotic function is important for understand-
ing these disease states and how they might be best
treated.
Two major pathways leading to apoptosis have been
delineated: the extrinsic or receptor-mediated pathway,
and the intrinsic or mitochondrial pathway (Figure 1).3
Both pathways involve the activation of a cascade of en-
zymes called caspases, a family of cysteine proteases that
cleave after aspartic acid residues. Caspases are initially
synthesized as zymogens, and during activation they are
processed at a caspase cleavage site to generate their active
forms. The extrinsic and intrinsic pathways have an inde-
pendent group of “initiator” caspases, and the pathways
converge to utilize the same group of “effector” caspases
that execute the final cell death program.
The extrinsic or receptor-mediated pathway is char-
acterized by the activation of cell surface death recep-
tors following binding of their specific ligand (Figure 1).
These death receptors belong to the tumor necrosis fac-
tor/nerve growth factor receptor superfamily, and include
such members as Fas, TNFR1, TRAMP, and the TRAIL
receptors.4 These receptors are characterized by a cysteine-
rich repeat in their extracellular domain and a conserved
cytoplasmic sequence called the death domain. Ligand
binding to the extracellular domain of the death recep-
tor results in receptor trimerization, with the subsequent
recruitment of the adaptor molecule FADD to the death
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Figure 1. The extrinsic and intrinsic pathways of apoptosis. The extrinsic pathway is triggered following ligand binding to receptors of the
tumor necrosis factor (TNF) superfamily, leading to receptor multimerization. The adaptor molecule FADD then binds to the cytoplasmic
domain of the receptor, and initiator caspases bind to the death effector domain of FADD. Initiator caspases undergo autocatalytic
processing resulting in subsequent activation of effector caspases, including caspase-3, -6, and -7. The intrinsic pathway of apoptosis
is triggered following mitochondrial damage, which leads to cytochrome c release. There is subsequent formation of the apoptosome, a
multiprotein complex containing cytochrome c, Apaf-1, and caspase-9. Following caspase-9 activation, the intrinsic pathway converges
with the extrinsic pathway at the level of effector caspase activation, and these effector caspases carry out the apoptotic cell death
program.
domain on the cytoplasmic face of the receptor. This adap-
tor molecule is able to recruit initiator procaspase-8 and/or
procaspase-10. Following recruitment, the high local con-
centration of the procaspase molecules promotes auto-
catalysis to their active forms. These activated initiator
caspases are then able to carry out the downstream pro-
teolytic processing of the effector caspases-3, -6, and -7,
which execute the cell death program.
The intrinsic or mitochondrial pathway can be exe-
cuted independent of death receptor signaling, and also
results in the activation of effector caspases (Figure 1).
The essential components of this pathway were identified
through a biochemical approach in a cell-free system. In
a now well-characterized process, mitochondrial damage
results in the leakage of cytochrome c into the cytoplasm.
Subsequently, cytochrome c complexes with the cytoplas-
mic protein Apaf-1, which then oligomerizes and binds to
procaspase-9, resulting in the formation of a multimeric
complex called the apoptosome. This brings procaspase-9
molecules into close proximity with each other, allow-
ing enzymatic self-activation. Caspase-9 is then is able to
cleave and activate the downstream effector caspases-3,
-6, and -7.5–7
Since the original identification of Apaf-1,7 its struc-
ture and function in the apoptosome have been further
characterized. The primary structure of Apaf-1 consists
of an amino-terminus with 12 or 13 WD-40 repeats, a
central ATPase domain with homology to CED-4, and
a carboxy-terminal caspase recruitment domain (CARD).
There are four major isoforms of the protein that are de-
fined by the presence or absence of two sequences, an
11 amino acid insert between the ATPase domain and
CARD, and an additional WD-40 repeat between repeats
5 and 6.8 Studies have shown that this additional WD-
40 repeat, and thus a total of 13 repeats, is necessary
for caspase-9 activation in response to cytochrome c and
dATP.8 Analysis of the three-dimensional crystal struc-
ture of the apoptosome has revealed a model in which cy-
tochrome c binds to the WD-40 repeat region, and dATP
binds to the ATPase domain of Apaf-1. This results in a
conformational change in Apaf-1, and the formation of a
wheel-like apoptosome structure containing seven Apaf-1
molecules.9 In the apoptosome complex, Apaf-1 interacts
with the adjacent Apaf-1 molecules via their N-terminal
CARD domains to form a central hub region, and the C-
terminal WD40 repeats are extended to form the outside
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ring.10 Each Apaf-1 molecule is bound to procaspase-9 via
a CARD-CARD interaction.9 It appears that the WD-40
repeat region of Apaf-1 functions to inhibit apoptosome
formation, as the deletion of the WD-40 region results in
constitutively active Apaf-1 that facilitates caspase-9 ac-
tivation in the absence of cytochrome c .11 Additionally, a
number of modulators of apoptosome formation and func-
tion have been described and will be discussed in further
detail below.
Unlike initiator caspases that are activated through an
autocatalytic process, effector caspases such as caspase-3,
-6, and -7 are cleaved by another caspase that enzymati-
cally removes the short prodomain of the effector caspase.
Once activated, the effector caspases degrade vital cellular
proteins, leading to cell death. Specific substrates of these
caspases include structural proteins such as actin and nu-
clear lamin, regulatory proteins such as DNA-dependent
protein kinase, and inhibitors of deoxyribonuclease.12 The
cellular proteolysis carried out by effector caspases results
in the biochemical and morphological cellular changes
characteristic of apoptosis, including nuclear membrane
breakdown, DNA fragmentation, chromatin condensa-
tion, and the formation of apoptotic bodies.13
Recent data suggests that the two pathway model of
apoptosis is oversimplified, and that there is cross-talk
between the extrinsic and intrinsic pathways of apop-
tosis. The extrinsic pathway initiator caspase, caspase-
8, has been shown to cleave the BH3-only protein Bid,
which then mediates mitochondrial membrane perme-
abilization and cytochrome c release.14 This mechanism
leads to mitochondrial amplification of the extrinsic path-
way signal. Other studies have suggested that there is
caspase activation prior to disruption of mitochondrial
membrane integrity. For example, cytotoxic stress ac-
tivates caspase-2, leading to translocation of the pro-
apoptotic protein Bax to the mitochondria and subsequent
cytochrome c release.15 Through inhibition of caspase-2
activation, investigators demonstrated that in their exper-
imental system, caspase-2 is necessary for mitochondria-
mediated apoptosis.15 A role for caspase-2 activation up-
stream of mitochondrial disruption has also been sup-
ported by additional studies.16 This data suggests that
there is caspase activation prior to mitochondrial perme-
abilization. Finally, recent studies suggest that caspase-
9 activation can occur independent of the apoptosome.
In one such study, TNF-receptor-induced apoptosis in-
cludes activation of caspase-9 even in the absence of
Apaf-1.17
Cellular homeostasis is the result of maintaining a deli-
cate balance between cell growth and death. The inability
of cells to undergo apoptosis in response to specific cues
can lead to overgrowth and the development of malig-
nancy. Thus, specific defects in the normal apoptotic path-
ways described above can result in tumorigenesis, and a
number of recent reports suggest that apoptosome defects
may contribute to the development of human cancers.
Therapeutic modalities for cancer, e.g., chemotherapy and
radiation therapy, induce cell death through activation of
the mitochondrial pathway of apoptosis. Therefore, tu-
mor resistance to therapy may result from alterations to
the normal pathway of apoptosome-initiated cell death. A
number of endogenous modulators of apoptosome func-
tion have been identified and serve as potential sites at
which defects in the cell death program develop. In this
review we will summarize the current understanding of
the modulation of apoptosome formation and function,
and address how these mechanisms may be altered in hu-
man cancers to promote both tumorigenesis and tumor
resistance to standard therapies.
Modulation of apoptosome formation
and function
Inhibition of cytochrome c release
Since the intrinsic, mitochondrial pathway of apoptosis
was first described, a number of factors that regulate apop-
tosome formation and execution of downstream signals
have been identified (Figure 2). As discussed above, the
initial step in activation of the intrinsic pathway for apop-
tosis is the release of cytochrome c from the mitochondria.
Bcl-2 proteins have been described as guardians of mito-
chondrial cytochrome c release. Bcl-2-related proteins can
be divided into two groups: the anti-apoptotic Bcl-2 fam-
ily and the pro-apoptotic Bax and BH3-only proteins.18
Interactions between Bcl-2 family members with oppos-
ing effects establish a balance between anti-apoptotic and
pro-apoptotic cellular signals.
Bcl-2 family members, including Bcl-2 and Bcl-xL,
contain at least one Bcl-2 homology domain (BH), and
are localized to the cytoplasmic face of the outer mito-
chondrial membrane, the endoplasmic reticulum, and the
nucleus. Current data suggest that in mammalian cells,
these proteins function in the maintenance of membrane
integrity. Pro-survival Bcl-2 family members prevent cy-
tochrome c release from mitochondria, thus blocking the
downstream intrinsic pathway events of apoptosome for-
mation and caspase activation.18 This function for Bcl-2 is
supported by the findings that it is an integral membrane
protein19 and is able to prevent cytochrome c release.20,21
In contrast, in C. elegans, Bcl-2 homologs bind the Apaf-1
homolog CED-4 to sequester it and prevent apoptosome
formation until pro-apoptotic signals are received. Studies
have shown that Bcl-2 and Apaf-1 do not bind in mam-
malian cells,22 supporting a membrane integrity model
rather than a sequestration model for Bcl-2 function.
These anti-apoptotic effects of Bcl-2 proteins are coun-
tered by the actions of the pro-apoptotic actions of Bax
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Figure 2. Apoptosome formation and its regulation. The formation of the apoptosome is a multistep process following mitochondrial
damage. The major steps are shown in the figure, with key regulators for each step indicated. See the text for a thorough discussion of
the regulation of apoptosome formation at each of these steps.
and BH3-only proteins. The physiologic role of these pro-
teins is to sensitize cells to apoptosis. Mitochondrial mem-
brane integrity is disrupted when BH3-only proteins,
such as Bim, Bik, and Bad, bind to and neutralize the anti-
apoptotic Bcl-2 proteins. Subsequently, pro-apoptotic Bax
subfamily members, including Bax and Bak, form homo-
oligomers in the mitochondrial membrane, thus altering
membrane permeabilization and allowing cytochrome c
efflux.23 In support of this model, Bax family members are
able to form pores in liposomes, resulting in cytochrome
c transport.24–26 Once cytochrome c is released from the
mitochondria to the cytoplasm, it binds Apaf-1. Apaf-
1 then undergoes a conformational change as described
above with resultant apoptosome formation and caspase
activation.
The presence of at least twenty mammalian Bcl-2 fam-
ily members speaks to the intricacy of apoptosis regula-
tion in mammals. Numerous studies have illustrated the
need for both the pro-apoptotic and anti-apoptotic Bcl-
2-related proteins. For example, the importance of pro-
apoptotic Bax proteins has been demonstrated through
studies finding that BH3-only proteins are unable to kill
cells in the absence Bax and Bak27,28 and mouse knock-
out studies have demonstrated that either Bax or Bak is
required for stress-induced apoptosis.29
There are multiple mechanisms of regulation of Bcl-
2 family members, including the Bax and BH3-only
subfamilies.18 One such mechanism of regulation is the
phosphorylation of the pro-apoptotic protein Bad by
the serine-threonine kinase Akt, thus inhibiting Bad’s
function.30,31 The ability of Akt to phosphorylate Bad
and block its pro-apoptotic function is consistent with the
pro-survival signals mediated by the phosphatidylinosi-
tol 3-kinase (PI3K) pathway that signals through the tar-
get protein Akt. Another important link between cellular
metabolism and the apoptotic pathway has recently been
elucidated. Pro-apoptotic Bad has been shown to com-
plex with glucokinase, the first enzymatic step of multiple
glucose metabolism pathways.32 Glucose deprivation of
cells causes dephosphorylation of Bad and Bad-dependent
apoptosis.32 This work establishes an important new link
between glucose homeostasis and apoptosis.
Cytochrome c may be inhibited following release from
the mitochondria, thus preventing apoptosome formation
and apoptosis. One study investigating the mechanism
of UV-induced apoptosis in MCF-7 breast cancer cells
demonstrates release of mitochondrial cytochrome c fol-
lowed by effector caspase-mediated apoptosis (cleavage of
PARP) in the absence of caspase-9 cleavage.33 In response
to UV stimuli or treatment with valinomycin, mitochon-
drial cytochrome c was released , however, pro-caspase-9
was not cleaved in MCF-7 cells unless exess exogenous
cytochrome c was added. The authors postulate the pres-
ence of a novel cytoplasmic inhibitor of cytochrome c 33;
however, additional studies are needed to identify and
characterize such a potential inhibitor.
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Inhibition of apoptosome formation
Following cytochrome c release, the next step in the
intrinsic pathway of apoptosis is the formation of the
apoptosome. There are multiple factors that regulate this
stage of the pathway (Figure 2). Heat shock proteins
(HSPs) are a family of highly conserved proteins that are
induced in response to a variety of cellular stresses and
function to protect the cell. These proteins have been
found to inhibit apoptosome formation in a number of
reports, thus serving to suppress apoptosis in response
to physiological and environmental stresses.34 Hsp70 is
a central protein in the cellular stress response system.
Hsp70 has been shown to bind to the CARD domain of
Apaf-1, with the resultant inhibition of apoptosome for-
mation including an inability to recruit procaspase-9 to
the complex.35,36 Different reports have disputed whether
Apaf-1 oligomerization is able to proceed in the presence
of Hsp70.35,36 Interestingly, studies suggest that Hsp70
also functions to inhibit apoptosis independently of its
effect on apoptosome formation. In Apaf-1−/− mouse em-
bryo fibroblasts, Hsp70 overexpression protects the cells
from apoptosis following serum withdrawal.37 Hsp70
carries out this function by binding to apoptosis-inducing
factor (AIF), a mitochondrial intermembrane flavoprotein
that, upon release into the cytoplasm, translocates to the
nucleus and induces caspase-independent apoptosis.38
Both Hsp90 and Hsp27 have also been shown to inhibit
apoptosome formation. Hsp90 binds to Apaf-1 and in-
hibits Apaf-1 oligomerization and apoptosome formation
in response to cellular stresses.39 Studies suggest that
Hsp27 inhibits apoptosome formation by binding to and
sequestering both cytochrome c and procaspase-3.40,41
The modulation of apoptosome formation is a balance
between pro-apoptotic and anti-apoptotic signals. It has
been shown in in vitro experiments that apoptosis is reg-
ulated by intracellular potassium ion (K+) levels,42,43
with physiological intracellular K+ concentrations func-
tioning to inhibit apoptosome formation by preventing
Apaf-1 oligomerization.43 This inhibition is overcome by
increasing cytoplasmic concentrations of cytochrome c ,
and it is proposed that the mechanism for K+ inhibition
is through competition for cytochrome c binding sites on
Apaf-1.43 This inhibition of apoptosome formation by
physiologic concentrations of K+ may serve as a safety
mechanism against initiation of the apoptotic cascade fol-
lowing the leakage of small amounts of cytochrome c from
the mitochondria.
Finally, recent work has demonstrated that the on-
coprotein prothymosin-α (ProT) inhibits apoptosome
formation,44 suggesting that one mechanism by which the
protein is oncogenic is through the inhibition of apoptosis.
Pro-T has been described as a transforming oncoprotein
in vitro, and is associated with some human cancers.45,46
The precise molecular interactions by which ProT neg-
atively regulates apoptosome formation have yet to be
determined.
Modulation of caspase activation
The intrinsic pathway of apoptosis is also regulated by
through the modulation of caspase activation by multiple
proteins downstream of apoptosome formation (Figure 2).
The inhibitor of apoptosis (IAP) proteins were initially
identified in baculoviruses on the basis of their ability to
suppress cell death in response to viral infection. To date
over half a dozen human IAP proteins have been iden-
tified, including XIAP, cIAP1, cIAP2, NIAP, BRUCE,
ML-IAP and Survivin. These proteins all contain at least
one baculoviral IAP repeat (BIR) approximately 70 amino
acids in length that is required for their ability to inhibit
apoptosis. BIR domains 1 and 2 of IAPs bind and in-
hibit caspase-3 and -7, whereas the BIR3 domain binds
to and specifically inhibits caspase-9.47–49 Overexpression
of human IAPs has been shown to suppress apoptosis in
response to a number of stimuli, including those which
activate the intrinsic pathway of apoptosis.49 IAP pro-
teins appear to suppress apoptosis by directly inhibiting
specific caspases. The IAP proteins XIAP, cIAP1, cIAP2
can bind to procaspase-9 to prevent its processing and
activation.47 Additionally, IAP proteins function to block
the apoptotic cascade further downstream by binding to
and inhibiting effector caspases including caspase-3 and
caspase-7.47,50,51
While the IAPs function to inhibit caspase activation,
mammalian cells contain multiple proteins that func-
tion to remove this inhibition and promote apoptosis.
Smac and its murine homolog DIABLO are normally lo-
calized to the mitochondrial intermembrane space, and
are released into the cytosol in response to mitochon-
drial damage. Once in the cytosol, the pro-apoptotic pro-
tein Smac/DIABLO interacts with IAP family members
to remove their inhibition of caspases.52,53 HtrA2/Omi
is another protein that functions to relieve IAP inhibi-
tion of caspases.54–58 HtrA2/Omi is also released from
the mitochondrial intermembrane space in response to
mitochondrial damage, allowing it to interact with IAPs
in the cytosol. Unlike Smac/DIABLO, HtrA2/Omi not
only is able to bind to and inhibit IAPs, but it also has
serine protease activity that facilitates cell death.55,58,59
The structural and biochemical basis of the interaction
between these proteins and the IAPs has been reviewed
elsewhere.12
As discussed above, the serine-threonine kinase Akt
mediates survival by phosphorylating and inactivating the
pro-apoptotic protein Bad. In effecting its pro-survival
signal, Akt also modulates caspase activation. Akt phos-
phorylation of procaspase-9 blocks cleavage of procaspase-
9 and subsequent activation of procaspase-3.60 Taken
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together, these data demonstrate that Akt has multiple
targets, the phosphorylation of all of which promotes cell
survival by inhibiting the intrinsic pathway of apopto-
sis. These findings are consistent with the pro-survival
effects of the growth factor signaling pathways through
PI3K/Akt.
In the search for small molecule activators of caspase-
3, investigators identified a small molecule with pro-
apoptotic effects mediated by a family of proteins named
putative HLA-DR-associated proteins (PHAP).44 Stud-
ies into the mechanism by which this pro-apoptotic agent
functions demonstrated that recombinant PHAPI did not
affect the efficiency of apoptosome formation, but did
promote caspase-9 activation.44 The precise molecular
mechanism through which the PHAP proteins promote
caspase activation is unclear at this time. However, this
pro-apoptotic role for PHAPs is consistent with work
demonstrating a tumor suppressor role for the pro-
teins. Overexpression of PHAPs has been shown to in-
hibit transformation of cell lines by known oncogenes,
while inhibition of PHAPs causes development of tu-
morigenic cellular characteristics such as loss of con-
tact inhibition and development of serum-independent
growth.61,62
Table 1. Intrinsic pathway defects in human cancers. Studies have demonstrated alterations in the intrinsic pathway of apoptosis at all
steps in the pathway, from cytochrome c release to apoptosome formation to caspase activation. Shown here are the pathway step, the
defect, and the tumor type in which the results were obtained. These data represent work in primary tumors. Findings in cancer cell lines
are discussed in the text but not listed here
Intrinsic pathway step Specific defect Tumor type Reference
Cytochrome c release Bcl-2 overexpression Follicular lymphoma [107]
Bcl-xL overexpression Breast, pancreatic, ovarian, colorectal,
esophageal squamous cell carcinomas
[66–71]
Bax or Bak loss-of- Colon cancer [73]




Breast, ovarian, pancreatic, prostate,
thyroid cancers
[94–98]
Apoptosome formation Decreased or absent Ovarian cancer [82,83]
Apaf-1 activity Melanoma [77]
Leukemia [81]





ProT overexpression Colon cancer [90]
Hepatocellular carcinoma [89]
Caspase activation Akt overexpression
(phosphorylation of
procaspase-9)
Breast, ovarian, pancreatic, prostate,
thyroid cancers
[93–97]





XIAP overexpression Acute myelogenous leukemia [103]
ML-IAP overexpression Melanoma [104,105]




Cancer arises due to a disruption in the balance between
cell growth and cell death. Defects in the execution of
cell death may arise due to alterations in the regula-
tion of apoptosis. The loss of pro-apoptotic signals in
response to appropriate stimuli can contribute to aber-
rant cell growth. Additionally, the overexpression of anti-
apoptotic signals can prevent cell death in situations that
would normally result in the activation of the apoptotic
cascade. Defects within the intrinsic pathway have been
shown to be important in the pathogenesis of a num-
ber of human malignancies, with these alterations aris-
ing at a variety of possible steps within the pathway
(Table 1).
Disruption of the balance between pro-apoptotic and
anti-apoptotic stimuli in human cancers can be attributed
to alterations in the expression of Bcl-2 family mem-
bers that have opposing functions. The pro-survival Bcl-
2 subfamily members are likely oncogenic, while the
pro-apoptotic Bax and Bak proteins may function as
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tumor suppressors. Bcl-2 was first shown to be overex-
pressed in human cancer when it was identified as part
of a translocation involving the immunoglobulin locus in
follicular lymphoma.63 A causative role for Bcl-2 in cel-
lular transformation was then demonstrated with a trans-
genic mouse model in which animals overexpressing Bcl-2
develop primitive lymphoid tumors.64 Bcl-2 overexpres-
sion has now been demonstrated in many human malig-
nancies, including hematopoietic cancers, breast cancer,
prostate cancer, and follicular lymphoma.65 The Bcl-2 ho-
molog, Bcl-xL, is overexpressed in breast, pancreatic, col-
orectal, and esophageal squamous cell carcinomas.66–71
The pro-apoptotic Bak subfamily members also appear
to be important in human cancers, where they function
as tumor suppressors. Bax was first shown to function
as a tumor suppressor in transgenic mouse brain tumor
model.72 Studies have demonstrated loss-of-function mu-
tations in Bax and related protein Bak in gastric, col-
orectal, and hematopoietic malignancies.73–76 Finally, it is
likely that BH3-only proteins may function as tumor sup-
pressor proteins as well based on their ability to promote
apoptosis.
Following cytochrome c release, the next step in the
intrinsic pathway of apoptosis is apoptosome formation.
Defects in apoptosome proteins themselves, such as Apaf-
1, have been implicated in human malignancies. The first
report of Apaf-1 inactivation in human cancer was the
demonstration that malignant melanomas fail to express
this protein.77 Loss of heterozygosity at the Apaf-1 gene
locus was demonstrated at a high rate and the second
allele was shown to be inactivated via methylation.77 Ad-
ditional studies have shown that the frequency of Apaf-
1 loss is higher in metastatic melanomas than primary
melanomas,78,79 and loss of Apaf-1 in melanomas is cor-
related with a poorer patient prognosis.79 The finding
that both Apaf-1 alleles are inactivated supports the hy-
pothesis that Apaf-1 functions as a tumor suppressor in
malignant melanoma. Apaf-1 loss has been reported in ad-
ditional tumor types including glioblastomas,80 leukemia
cell lines,81 and ovarian cancer.82,83 In ovarian cancer cell
lines, Apaf-1 is still expressed but there is decreased func-
tional activity of the protein.82 This finding in ovarian
cancer cell lines has been validated and also extended
to human ovarian cancer tumor specimens.83 This im-
pairment of apoptosome function is not due to suppres-
sion by known inhibitors,83 suggesting the possibility of
the presence of a novel protein that modulates Apaf-1
function.
Alterations in the expression of proteins that regu-
late apoptosome formation have also been proposed to
play a role in carcinogenesis, including overexpression of
HSPs and ProT. As discussed previously, HSP overex-
pression functions to inhibit apoptosome formation and
apoptosis, thus these proteins may be oncogenic. Many
studies have demonstrated an upregulation of HSP ex-
pression in human tumors, including breast, gastric, en-
dometrial, lung, and hematopoietic malignancies.84 The
overexpression of HSPs has been shown to be correlated
with poorer clinical outcomes. For example, expression
of Hsp70 in breast cancer is correlated with a shorter
disease-free survival interval and an increased frequency
of metastasis.85,86 HSP overexpression in breast cancer pa-
tients also correlates with a decreased responsiveness to in-
duction chemotherapy.86 Clinical and prognostic findings
similar to these for Hsp70 have been reported for other
HSPs.84 In support of a causative role for the overexpres-
sion of HSPs in cancer, many cancer cell lines demonstrate
an increased level of expression of Hsp70 and resistance to
apoptosis, and some studies report that decreasing levels
of Hsp70 in these lines can promote apoptosis.87
ProT has been shown to suppress apoptosome
formation,44 and this may explain the known oncogenic
properties of this protein. In vitro studies have demon-
strated that ProT is capable of inducing cellular trans-
formation of rodent fibroblasts.46 Multiple studies have
demonstrated increased expression of ProT in human ma-
lignancies compared to normal tissue controls, in can-
cer types including lung,88 hepatocellular,89 breast,45
and colon.90 In lung and breast cancers, the overexpres-
sion of ProT has been correlated with a poorer patient
prognosis.45,88 Such findings are complicated, however,
by data suggesting that ProT may be a c-myc target
gene,91,92 in which case such correlations may reflect el-
evated expression of the c-myc oncogene in those tumor
types, without ProT overexpression necessarily contribut-
ing to cellular transformation. With the new finding that
ProT suppresses apoptosome formation, one can now pos-
tulate that it is through the inhibition of apoptosis that
this protein independently serves as an oncoprotein both
in vitro and also potentially in vivo.
As discussed previously, the kinase Akt functions to
regulate the intrinsic pathway of apoptosis at multi-
ple levels, including inhibiting cytochrome c release by
phosphorylating Bad and phosphorylating procaspase-9
to block its activation. Akt lies downstream of PI3K in a
cell survival cascade that is activated in response to mul-
tiple growth factors.93 Many studies have demonstrated
that constitutive expression of enzymatically-active Akt
results in the inhibition of apoptosis in response to
agents that normally trigger the intrinsic pathway, and
dominant-negative Akt prevents growth factor-mediated
cell survival signaling.93 It is plausible that the oncogenic
properties of signaling molecules lying upstream of Akt
are mediated, at least in part, by the anti-apoptotic ef-
fects of Akt on the intrinsic pathway. Upregulation of
Akt has been demonstrated in many human tumors, in-
cluding breast, ovarian, pancreatic, prostate, and thyroid
carcinomas.94–98
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Alterations in other proteins that regulate caspase ac-
tivation, such as IAPs, Smac/DIABLO, HtrA2/Omi, and
PHAP may also contribute to cancer development and
progression. Of the IAP proteins identified in humans,
Survivin appears to have the most clinically relevant link
to cancer. This protein has been shown to be overex-
pressed in cancers but not in normal tissue nor surround-
ing stroma.99 Additionally, in in vitro studies, decreasing
Survivin levels has been shown to cause apoptosis and an
increased sensitivity to chemotherapeutic agents.100 Sur-
vivin overexpression has also been correlated with poorer
prognosis in a wide variety of tumor types.45 It should
be noted, however, that Survivin appears to function in
the mitotic machinery101 and its function in inhibiting
apoptosis is still disputed.102 Another IAP, XIAP, has
been shown to be overexpressed in acute myelogenous
leukemia.103 Finally, the IAP ML-IAP is overexpressed in
melanoma.104,105
With regard to the recently identified tumor suppres-
sor PHAPI, the loss of normal PHAP expression has been
demonstrated in prostate adenocarcinoma.62 The tumor
suppressor function of this family of proteins has been
demonstrated by a number of independent groups who
show that PHAPs are able to inhibit transformation of
cell lines by known oncogenes.61,62 Thus the modulation
of caspase activation, either through inhibition or activa-
tion, can affect cellular growth properties and potentially
contribute to tumorigenesis.
Intrinsic pathway defects contribute to cancer
treatment resistance
Cancer therapies can exploit the normal cell death path-
ways to kill cells. Indeed, the common cancer treatment
modalities of chemotherapy and radiation therapy pri-
marily cause mitochondrial disruption and activation of
the intrinsic pathway of apoptosis to trigger cell death.
The intrinsic pathway defects discussed above may con-
tribute to carcinogenesis, and may also serve as mecha-
nisms of resistance to standard cancer therapies.106 Cor-
relations between intrinsic pathway defects and altered
patient outcomes found in clinical studies are likely sec-
ondary to poorer patient response to treatments due to
impaired functioning of the cell death pathway. Addi-
tionally, many studies performed with cancer cell lines
have demonstrated at a molecular level that defects in the
molecules required for execution of the intrinsic path-
way of apoptosis account for resistance to therapeutic
agents.
Research suggests that alterations in Bcl-2 expression
contribute to drug resistance observed in cancer cells.
These data include clinical studies showing a correlation
between high levels of Bcl-2 expression and poor clini-
cal outcomes107,108 and experiments demonstrating that
overexpression of Bcl-2 can result in drug resistance in
cancer cell lines.109 Similar findings have been reported
for the Bcl-2 homolog Bcl-xL, suggesting that its over-
expression may also contribute to resistance to cancer
treatments.66–71,106 The role of alterations in the pro-
apoptotic Bak and BH3-only subfamilies remains to be
more fully investigated.
One example of the role of intrinsic pathway defects in
treatment resistance is the finding that alterations in Apaf-
1expression or function result in drug resistance. Apaf-1
deficiency accounts for defective stress-induced apoptosis
in human leukemia cell lines and a cervical cancer cell
line, with the reintroduction of Apaf-1 into these cells
resulting in restoration of apoptosis.81,110 In ovarian can-
cer cell lines, defective Apaf-1 function is correlated with
chemoresistance.82,83 In a human prostate cancer cell line,
an alternatively spliced form of Apaf-1 is expressed and the
cells demonstrate impaired apoptosis, but reintroduction
of full-length Apaf-1 restores the apoptotic pathway.111
These studies are important in demonstrating a causative
role for Apaf-1 defects in therapy resistance, based on the
ability of the cell death pathway and drug sensitivity to
be restored following reintroduction of Apaf-1.
At the level of caspase activation within the intrinsic
pathway there are also potential defects that contribute to
drug resistance within cancer cells. A number of studies
have implicated activated Akt in the chemoresistant phe-
notype of tumor cells. Akt modulates cisplatin resistance
in ovarian cancer cells, with expression of active Akt caus-
ing chemoresistance and expression of dominant-negative
Akt resulting in sensitivity to standard chemotherapeutic
agents.112–114 Similar findings have also been reported in
breast cancer cell lines.115 In ovarian cancer cell lines resis-
tant to chemotherapeutic agents, down-regulating XIAP
can induce cellular apoptosis.116 This suggests that the
overexpression of XIAP in these lines in contributies to
chemoresistance. In addition, overexpression of XIAP and
other IAPs, including NIAP, cIAP1, and cIAP2, has been
reported to result in decreased sensitivity to chemothera-
peutic agents in vitro.117 The ability of XIAP overexpres-
sion to confer chemoresistance to tumor cells may be in
part due to XIAP up-regulating the PI3K/Akt pathway,
resulting in phosphorylation and activation of Akt, which
then can exert its anti-apoptotic effects.113,118
Targeting intrinsic pathway defects
for therapeutic intervention
As cancer treatment approaches move toward targeting
the specific molecular aberrations present in tumor cells,
the intrinsic pathway of apoptosis is an excellent site for
such targeted therapies.119 Targeted therapeutics focused
upon defects in the intrinsic pathway have two poten-
tial mechanisms of facilitating cell death in cancer cells.
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The first is to restore the normal apoptotic pathway so
that cells regain sensitivity to standard chemotherapeutic
agents. Such an approach has been illustrated above in
considering apoptosome defects in human cancers, with
multiple groups showing that reintroduction of a protein
required for apoptosome function restores chemosensitiv-
ity. Another mechanism to induce cell death in cells with
defects in the intrinsic pathway is to trigger and drive
apoptosis in the absence of additional signals. This ap-
proach has been most strongly exploited in attempts to
disrupt Bcl-2 function in cancer cells, but other specific
molecules are being targeted as well.
Overexpression of the anti-apoptotic family members
Bcl-2 and Bcl-xL is proposed to occur in over half of
all human cancers,120 and multiple techniques are be-
ing used to decrease expression of these proteins in the
attempt to alter tumor growth. One approach has been
to use antisense nucleotides, such as an oligonucleotide
complementary to the first 18 nucleotides of the Bcl-2
coding sequence called G3139. This antisense nucleotide
has been shown to result in downregulation of Bcl-2 and
improved patient outcomes,121 leading to the initiation of
additional clinical studies on the molecule. For example,
phase III randomized clinical trials with Bcl-2 antisense
oligonucleotides are ongoing in patients with solid breast
tumors.122 Gene therapy approaches are also being devel-
oped to disrupt Bcl-2 function in cancer cells. Adenovirus
expressing Bcl-xs, a splice variant of Bcl-x that acts as a
dominant negative repressor of Bcl-2 and Bcl-xL, is able to
induce apoptosis of breast cancer cells in a mouse model123
and a clinical trial using the Bcl-xs adenovirus is currently
underway.124 A number of additional approaches are be-
ing investigated to interfere with Bcl-2 function in tumor
cells, including the use of peptide analogs of BH3-only
proteins125 and the design of small molecule inhibitors of
Bcl-2.119,126
In addition to targeting Bcl-2, other proteins impor-
tant in the intrinsic pathway of apoptosis are being tar-
geted to treat cancer cells. Given the central location of
the PI3K/Akt pathway downstream in many growth fac-
tor signaling cascades and its dysregulation in human
cancers, Akt represents an excellent target for molecu-
lar therapeutics.127 One Akt small molecule inhibitor,
perifosine, is currently in phase II clinical trials for the
treatment of a number of solid tumor malignancies.128,129
Additional small molecule inhibitors of Akt are being in-
vestigated, including phosphatidylinositol analogs that
block Akt activation130,131 and the natural plant product
deguelin,132 although the specificity of such compounds
for Akt remains to be more clearly demonstrated.
Another approach that has been investigated by a
number of groups is to release the endogenous suppres-
sion of caspases by IAPs, so that the caspases can then
trigger cell death. A number of endogenous IAP in-
hibitors have been identified, including Smac/DIABLO
and Omi/HtrA2. Two groups have reported the introduc-
tion of Smac peptides into tumor cells to inhibit IAPs and
therefore allow caspase activation.133,134 Interestingly, in
both of these reports the Smac peptide was not suffi-
cient to result in cell killing, but did provide chemosen-
sitization so that tumor cells responded to conventional
chemotherapy.133,134 In a similar approach to block IAP
suppression of caspases, a recent paper reports the identi-
fication of eight polyphenylurea compounds that function
as small molecule inhibitors of XIAP, with testing of the
compound 1396-34 in multiple cell culture and animal
tumor models.135 Of note, this polyphenylurea compound
releases XIAP suppression of an effector caspase, caspase-
3, resulting in direct cell killing without the need for
adjuvant chemotherapy.135 This suggests that caspase-3
is already active in tumor cells, with its apoptotic effects
being held in-check by XIAP,136 a hypothesis supported
by the finding that processed caspase-3 is present in tumor
cells.137 It is proposed that the differential requirement
for adjuvant chemotherapy with Smac mimetics as com-
pared to the XIAP small molecule inhibitor is based on
the different site to which the two compounds bind on
XIAP, with Smac peptides only releasing caspase-9 inhi-
bition, and the XIAP small molecule inhibitor releasing
caspase-3 inhibition.136 Additional approaches to block
IAP suppression of caspases are also being explored, in-
cluding the use of antisense oligonucleotides to XIAP.119
Inhibition of the IAP Survivin has been carried out us-
ing antisense and dominant-negative constructs expressed
either on plasmids or adenoviral vectors.138–140
Discussion
The molecular players in the intrinsic pathway of apop-
tosis are becoming increasingly well-characterized, form-
ing a picture of an intricately regulated pathway for type
I programmed cell death. The intrinsic pathway can be
considered to occur in three major steps, the release of
cytochrome c from mitochondria, apoptosome formation
with initiator caspase activation, and effector caspase ac-
tivation and execution of the cell death program. As out-
lined above, each of these steps is regulated by multiple
proteins that themselves are subject to regulation. Defects
in pathway proteins or their regulators may contribute to
both tumorigenesis and drug resistance, and may repre-
sent novel targets for molecular therapeutics.
Both expression studies in primary tumors and mech-
anistic studies in the cell culture setting suggest that
deregulation of the intrinsic pathway of apoptosis is im-
portant in cancer development and progression. However,
the question remains as to whether the intrinsic path-
way is truly essential in carrying out stress-induced cell
death, or whether the pathway merely functions to am-
plify the apoptotic signal.141,142 In both C. elegans and
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D. melanogaster, apoptosis takes place in a mitochondria-
independent manner.142 Gene knock-out studies in mice
have also raised the question as to the essential nature
of the intrinsic pathway, with aspects of the data both
supporting and arguing against the necessity of the mito-
chondrial pathway. Apaf-1 and caspase-9 knock-out mice
fail to undergo normal neuronal cell death and demon-
strate resistance to some methods of stress-induced apop-
tosis, suggesting that these proteins are necessary for
apoptosis. However, the animals continue to demonstrate
intact apoptotic mechanisms in some aspects of their
development.143 In independent work using cells defi-
cient for both Apaf-1 and caspase-9, it was demonstrated
that cells can still undergo stress-induced apoptosis, and
importantly Bcl-2 overexpression functions to protect
these cells from programmed cell death.144 This suggests
that Bcl-2 can act in a cytochrome c and apoptosome-
independent manner to protect cells, perhaps via a seques-
tration model in which Bcl-2 binds a CED-4 homolog
other than Apaf-1, analogous to apoptosis regulation in
C. elegans.142
These findings, in combination with the previously dis-
cussed data supporting cross-talk between the extrinsic
and intrinsic pathways of apoptosis, argue that perhaps
the intrinsic pathway functions to amplify the apoptotic
signal rather than as a mechanism by which caspase acti-
vation is initiated.141,142 How does one reconcile the data
for and against an essential role for the mitochondrial
pathway? There are a number of possible explanations,
primarily founded on the great complexity of the human
system. Likely there are yet unidentified proteins that
regulate apoptosis, including both caspases and also po-
tentially a CED-4 homolog other than Apaf-1 that serves
as a scaffold protein for caspase activation. It is also likely
that there is tissue specificity with regard to the proteins
expressed and pathways exploited in apoptosis, an argu-
ment easily supported by the observation that Apaf-1 and
caspase-9 knock-out mice demonstrate intact cell death
pathways in some but not all tissues.143 Finally, there may
be redundancy in function among apoptotic proteins, pro-
viding safety mechanisms for the cells and also making
delineation of the pathways more challenging.
The question as to the essential nature of the intrinsic
pathway of apoptosis has implications for understanding
the role of the pathway in human cancer development
and tumor resistance. Arguably, if the intrinsic pathway
is not essential then intrinsic pathway defects may not
result in impaired cell death contributing to tumorigene-
sis, as other apoptotic mechanisms remain intact. On the
other hand, even if the mitochondrial pathway is merely a
mechanism by which the death signal is amplified, it still
may be necessary to obtain the level of cell death required
to maintain tissue homeostasis. As reviewed above, there
is mounting data supporting a role for apoptosome de-
fects in human cancer, both based on expression studies
in tumors and mechanistic studies in tissue culture sys-
tems. Increasing evidence suggests that perhaps there are
non-apoptotic cell death mechanisms important in tissue
homeostasis that are altered in human cancer, including
the degradative pathway of autophagy.145 The prevailing
viewpoint at this time is that standard cancer treatments,
including chemotherapy and radiation therapy, trigger
the intrinsic pathway of apoptosis. If tumors demonstrate
resistance to these conventional treatment modalities, it
may be possible to restore the intrinsic pathway or bypass
the defect. Alternatively, defects in the intrinsic pathway
might signal the need for a broader approach to treatment,
such as activating the extrinsic pathway of apoptosis, or
other types of cell death such as autophagy or necrosis.
Future work will need to not only clarify the role of the
intrinsic pathway of apoptosis in human cancer and ther-
apeutic drug resistance, but also address the interplay be-
tween apoptotic and non-apoptotic mechanisms of cell
death in malignancy and its treatment.
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